Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

NCT03226522 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT03226522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03226522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
July 13, 2017
Completion date
April 17, 2020
Enrollment
366 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

agitation in patients with dementia of the alzheimer's type, agitation,psychomotor, alzheimer disease